Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic—an effective antiviral that has since successfully treated millions. But like many antivirals before it, ...

Elon Musk, the richest person alive and the co-head of President-elect Donald Trump’s new Department of Government Efficiency ...

Novel triple-drug therapies are showing promise for patients with various kinds of leukemia, researchers reported at the American Society of Hematology meeting in San Diego.

Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction ...

Immunome has a turbulent history, shifting focus from COVID-19 therapies to oncology. Read what the future may hold for this ...

Selinexor with ruxolitinib demonstrated encouraging efficacy with a manageable safety profile in patients with myelofibrosis ...

Find out more about the emerging field of glycobiology, which could potentially lead to a new type of cancer immunotherapy.

A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...